"GLP-1 Diabetes Drug Slows Parkinson's Progression in Small Trial"
A small mid-stage trial has shown that the diabetes drug lixisenatide, similar to Ozempic, helped slow the progression of motor disability in patients with early-stage Parkinson's disease. The drug, made by Sanofi, demonstrated potential in mitigating symptoms such as tremors and stiffness, but was also associated with an increased risk of gastrointestinal side effects. Larger and longer studies are needed to fully determine the efficacy and safety of this treatment for Parkinson's disease.